Take2 Technologies Limited v. Pacific Biosciences of California, Inc.

District Court, N.D. California·Decided November 6, 2023·No. 5:23-cv-04166·Unknown

Opinion

TAKE2 TECHNOLOGIES LIMITED, et Case No. 5:23-cv-04166-EJD al., Plaintiffs, MOTION TO DISQUALIFY v. Re: ECF No. 75 PACIFIC BIOSCIENCES OF Defendant. Plaintiffs Take2 Technologies Limited (“Take2”) and the Chinese University of Hong Kong move to disqualify the entire in-house legal department at Defendant Pacific Biosciences of California (“PacBio”). ECF No. 75 (“Mot.”). The Court heard oral arguments on October 26, 2023. Based on the submitted arguments and evidence, the Court GRANTS IN PART Plaintiffs’ motion and ORDERS the parties to meet-and-confer as to the appropriate scope of relief. Prior to August 2022, Ms. Yang Tang was employed as an attorney at Perkins Coie, the law firm that is presently representing Plaintiffs Take2 Technologies Limited (“Take2”) and the Chinese University of Hong Kong. Decl. Michael J. Wise (“Wise Decl.”) ¶ 2, ECF No. 75-1. Between April and July 2022, Ms. Tang billed over 65 hours on behalf of Take2, including preparation for the present lawsuit and evaluating the ’794 Patent-in-Suit. Id. In August 2022, Ms. Tang departed from Perkins Coie and accepted employment as a senior intellectual property in-house counsel at Defendant Pacific Biosciences of California. Decl. Yang Tang (“Tang Decl.”) ¶ 5, ECF No. 84; Wise Decl. ¶ 4. Before accepting the PacBio offer, Ms. Tang informed Perkins Coie of the offer, indicated that she would not be involved on any Take2 matters, and consulted outside counsel before accepting the offer. Tang Decl. ¶¶ 6–7. Approximately three months later, on December 14, 2022, Plaintiffs filed the present infringement action against PacBio in the District of Delaware. ECF No. 2. A few weeks later, Plaintiffs’ counsel sent a letter to Defendant’s litigation counsel, flagging Ms. Tang’s conflict and requesting confirmation of proper ethical screening within PacBio. Wise Decl., Ex. A (“Dec. 30 Letter”). In response, PacBio’s counsel confirmed—in a letter signed and certified by PacBio’s general counsel and Ms. Tang—that PacBio’s general counsel had instructed the company’s legal department that Ms. Tang was not to work on or discuss any Take2 matters. Wise Decl., Ex. B (“Jan. 24 Letter”). In addition to the written instructions, PacBio maintains a restricted document repository relating to the Take2 matter that Ms. Tang cannot access and affirmed that Ms. Tang will not be apportioned any fees relating to the matter. Id. PacBio additionally confirmed that it reiterated the screening instruction when Take2 filed the present lawsuit in December 2022. Id. After providing the requested certification, PacBio did not receive any further complaints from Plaintiffs regarding the adequacy of the ethical screens or an intent to move for disqualification at the time. Opp. 5. However, after PacBio moved to transfer the action from the District of Delaware to the Northern District of California, Plaintiffs’ counsel reminded PacBio of Ms. Tang’s conflict with the additional remark that—if the matter is transferred to this district—it “reserve[d] its rights to pursue all available remedies . . . include[ing] the right to move to disqualify PacBio’s legal department.” Wise Decl., Ex. C (“Mar. 30 Letter”). PacBio proceeded with and prevailed on its transfer motion. ECF No. 61. On September 20, 2023, Plaintiffs filed the instant motion to disqualify “PacBio’s in-house legal department from representing PacBio in the Instant Action.” Mot. 3. “The right to disqualify counsel is a discretionary exercise of the trial court’s inherent powers.” Certain Underwriters at Lloyd’s London v. Argonaut Ins. Co., 264 F. Supp. 2d 914, 918 (N.D. Cal. 2003); Nat’l Grange of Ord. of Patrons of Husbandry v. California Guild, 38 Cal. App. 5th 706, 713 (2019) (“Whether an attorney should be disqualified is a matter addressed to the sound discretion of the trial court.”). Furthermore, the Court must “apply state law in determining matters of disqualification.” In re Cnty. of Los Angeles, 223 F.3d 990, 995 (9th Cir. 2000). Motions to disqualify counsel are subjected to “particularly strict judicial scrutiny,” given the potential for tactical abuse. Optyl Eyewear Fashion Int’l Corp. v. Style Companies, Ltd., 760 F.2d 1045, 1050 (9th Cir. 1985); People ex rel. Dep’t of Corps. v. SpeeDee Oil Change Sys., Inc. (“SpeeDee Oil”), 20 Cal. 4th 1135, 1144 (1999) (“[J]udges must examine these motions carefully to ensure that literalism does not deny the parties substantial justice.”). A disqualification motion involves a “conflict between the clients’ right to counsel of their choice and the need to maintain ethical standards of professional responsibility.” Id. However, “while the ‘drastic measure’ of disqualification is ‘generally disfavored and should only be imposed when absolutely necessary,’ ‘[t]he important right to counsel of one’s choice must yield to ethical considerations that affect the fundamental principles of our judicial process.’” Diva Limousine, Ltd. v. Uber Techs., Inc., 2019 WL 144589, at *3 (N.D. Cal. Jan. 9, 2019) (internal citation omitted). The Court first considers whether Ms. Tang’s conflict may be imputed to her “firm” under the CRPC before turning to the proper scope of any such disqualification. A. Disqualification and Vicarious Imputation PacBio does not appear to dispute that—given her past work at Perkins Coie relating to Take2—Ms. Tang may not work on any matters at PacBio that involve Take2, as evidenced by the internal ethical screens PacBio promptly implemented around Ms. Tang. See, e.g., Jan. 24 Letter. The primary point of contention, therefore, is whether Ms. Tang’s conflict may be imputed to other “lawyers [] associated in [her] firm.” Cal. R. Prof. Conduct (“CRPC”) 1.10(a). The applicable framework for imputation of conflicts is set forth in Rule 1.10. See Klein v. Facebook, Inc., 2021 WL 3053150, at *4 (N.D. Cal. July 20, 2021) (analyzing vicarious disqualification under CRPC 1.10(a) and its comments). Rule 1.10(a) begins by establishing a general imputation of conflicts to other lawyers associated in the same firm as the prohibited lawyer. CRPC 1.10(a). The Rule then carves out two exceptions to the prohibition where the conflict arises from (1) the conflicted lawyer’s personal interest or (2) the lawyer’s association with a prior firm. CRPC 1.10(a)(1)–(2). Under the second exception, the CRPC does not impute conflicts to the firm if the lawyer (i) “did not substantially participate in the same or a substantially related matter,” (ii) is “timely screened from any participation in the matter and is apportioned no part of the fee,” and (iii) “written notice is promptly given to any affected former client.” CRPC 1.10(a)(2)(i)–(iii). In reviewing “substantial participation,” courts may consider several factors, such as “such as the lawyer’s level of responsibility in the prior matter, the duration of the lawyer’s participation, the extent to which the lawyer advised or had personal contact with the former client, and the extent to which the lawyer was exposed to confidential information of the former client likely to be material in the current matter.” CRPC 1.10 cmt. 1; Klein, Inc., 2021 WL 3053150, at *5 (addressing Comment 1 to Rule 1.10 in assessing prohibited layer’s participation). 1. Implied Waiver Before turning to the substantive analysis of Plaintiffs’ motion, the Court first addresses and rejects Defendant’s argument that Plaintiffs have implicitly waived their right to seek disqualification by delaying their motion. Opp. 8–10. Plaintiffs here made their motion as soon as the motion was available to them under the applicable rules of professional conduct, gave Defendant notice of the conflict within two weeks of filing their complaint, and take issue with a serious and undisputed conflict involving Ms. Tang’s prior work on the very patent-in-suit. Defendant’s reliance on the Court’s prior holdi

Free access — add to your briefcase to read the full text and ask questions with AI

Take2 Technologies Limited v. Pacific Biosciences of California, Inc., (N.D. Cal. 2023).

Take2 Technologies Limited v. Pacific Biosciences of California, Inc. (Take2 Technologies Limited v. Pacific Biosciences of California, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Kirk v. First American Title Insurance
183 Cal. App. 4th 776 (California Court of Appeal, 2010)
Certain Underwriters at Lloyd's, London v. Argonaut Insurance
264 F. Supp. 2d 914 (N.D. California, 2003)
Harrison v. Woodward
103 P. 933 (California Court of Appeal, 1909)
Cal. Self-Insurers' Sec. Fund v. Superior Court of Orange Cnty.
228 Cal. Rptr. 3d 546 (California Court of Appeals, 5th District, 2018)
Martinez v. State Farm Fire & Casualty Co.
4 F. Supp. 3d 1096 (D. Minnesota, 2014)